Maša Umićević Mirkov1, Luc Janss2, Sita H Vermeulen3, Mart A F J van de Laar4, Piet L C M van Riel5, Henk-Jan Guchelaar6, Han G Brunner1, Cornelis A Albers1, Marieke J H Coenen1. 1. Department of Human Genetics, Radboud University Medical Center, Nijmegen, The Netherlands. 2. Faculty of Science and Technology, Department of Molecular Biology and Genetics, University of Aarhus, Tjele, Denmark. 3. Department of Human Genetics, Radboud University Medical Center, Nijmegen, The Netherlands Department for Health Evidence, Radboud University Medical Center, Nijmegen, The Netherlands. 4. Department of Rheumatology, University Twente&Medisch Spectrum Twente, Enschede, The Netherlands. 5. Department for Health Evidence, Radboud University Medical Center, Nijmegen, The Netherlands. 6. Department of Rheumatology, Leiden University Medical Center, Leiden, The Netherlands.
Abstract
OBJECTIVES: Pharmacogenetic studies of tumour necrosis factor inhibitors (TNFi) response in patients with rheumatoid arthritis (RA) have largely relied on the changes in complex disease scores, such as disease activity score 28 (DAS28), as a measure of treatment response. It is expected that genetic architecture of such complex score is heterogeneous and not very suitable for pharmacogenetic studies. We aimed to select the most optimal phenotype for TNFi response using heritability estimates. METHODS: Using two linear mixed-modelling approaches (Bayz and GCTA), we estimated heritability, together with genomic and environmental correlations for the TNFi drug-response phenotype ΔDAS28 and its separate components: Δ swollen joint count (SJC), Δ tender joint count (TJC), Δ erythrocyte sedimentation rate (ESR) and Δ visual-analogue scale of general health (VAS-GH). For this, we used genome-wide single nucleotide polymorphism (SNP) data from 878 TNFi-treated Dutch patients with RA. Furthermore, a multivariate genome-wide association study (GWAS) approach was implemented, analysing separate DAS28 components simultaneously. RESULTS: The highest heritability estimates were found for ΔSJC (h(2)gbayz=0.76 and h(2)gGCTA=0.87) and ΔTJC (h(2)gbayz=0.62 and h(2)gGCTA=0.82); lower heritability was found for ΔDAS28 (h(2)gbayz=0.59 and h(2)gGCTA=0.71) while estimates for ΔESR and ΔVASGH were near or equal to zero. The highest genomic correlations were observed for ΔSJC and ΔTJC (0.49), and the highest environmental correlation was seen between ΔTJC and ΔVASGH (0.62). The multivariate GWAS did not generate excess of low p values as compared with a univariate analysis of ΔDAS28. CONCLUSIONS: Our results indicate that multiple SNPs together explain a substantial portion of the variation in change in joint counts in TNFi-treated patients with RA. In conclusion, of the outcomes studied, the joint counts are most suitable for TNFi pharmacogenetics in RA. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/
OBJECTIVES: Pharmacogenetic studies of tumour necrosis factor inhibitors (TNFi) response in patients with rheumatoid arthritis (RA) have largely relied on the changes in complex disease scores, such as disease activity score 28 (DAS28), as a measure of treatment response. It is expected that genetic architecture of such complex score is heterogeneous and not very suitable for pharmacogenetic studies. We aimed to select the most optimal phenotype for TNFi response using heritability estimates. METHODS: Using two linear mixed-modelling approaches (Bayz and GCTA), we estimated heritability, together with genomic and environmental correlations for the TNFi drug-response phenotype ΔDAS28 and its separate components: Δ swollen joint count (SJC), Δ tender joint count (TJC), Δ erythrocyte sedimentation rate (ESR) and Δ visual-analogue scale of general health (VAS-GH). For this, we used genome-wide single nucleotide polymorphism (SNP) data from 878 TNFi-treated Dutch patients with RA. Furthermore, a multivariate genome-wide association study (GWAS) approach was implemented, analysing separate DAS28 components simultaneously. RESULTS: The highest heritability estimates were found for ΔSJC (h(2)gbayz=0.76 and h(2)gGCTA=0.87) and ΔTJC (h(2)gbayz=0.62 and h(2)gGCTA=0.82); lower heritability was found for ΔDAS28 (h(2)gbayz=0.59 and h(2)gGCTA=0.71) while estimates for ΔESR and ΔVASGH were near or equal to zero. The highest genomic correlations were observed for ΔSJC and ΔTJC (0.49), and the highest environmental correlation was seen between ΔTJC and ΔVASGH (0.62). The multivariate GWAS did not generate excess of low p values as compared with a univariate analysis of ΔDAS28. CONCLUSIONS: Our results indicate that multiple SNPs together explain a substantial portion of the variation in change in joint counts in TNFi-treated patients with RA. In conclusion, of the outcomes studied, the joint counts are most suitable for TNFi pharmacogenetics in RA. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/
Authors: M Fabris; L Quartuccio; C Fabro; S Sacco; S Lombardi; R Ramonda; D Biasi; D Punzi; S Adami; I Olivieri; F Curcio; S De Vita Journal: Pharmacogenomics J Date: 2015-07-07 Impact factor: 3.550
Authors: Xia Jiang; Johan Askling; Saedis Saevarsdottir; Leonid Padyukov; Lars Alfredsson; Sebastien Viatte; Thomas Frisell Journal: Arthritis Res Ther Date: 2016-12-03 Impact factor: 5.156
Authors: Rosario Lopez-Rodriguez; Eva Perez-Pampin; Ana Marquez; Francisco J Blanco; Beatriz Joven; Patricia Carreira; Miguel Angel Ferrer; Rafael Caliz; Lara Valor; Javier Narvaez; Juan D Cañete; Maria Del Carmen Ordoñez; Sara Manrique-Arija; Yiannis Vasilopoulos; Alejandro Balsa; Dora Pascual-Salcedo; Manuel J Moreno-Ramos; Juan Jose Alegre-Sancho; Federico Navarro-Sarabia; Virginia Moreira; Rosa Garcia-Portales; Enrique Raya; Cesar Magro-Checa; Javier Martin; Juan J Gomez-Reino; Antonio Gonzalez Journal: PLoS One Date: 2018-05-07 Impact factor: 3.240
Authors: Aida Ferreiro-Iglesias; Ariana Montes; Eva Perez-Pampin; Juan D Cañete; Enrique Raya; Cesar Magro-Checa; Yiannis Vasilopoulos; Rafael Caliz; Miguel Angel Ferrer; Beatriz Joven; Patricia Carreira; Alejandro Balsa; Dora Pascual-Salcedo; Francisco J Blanco; Manuel J Moreno-Ramos; Sara Manrique-Arija; María Del Carmen Ordoñez; Juan Jose Alegre-Sancho; Javier Narvaez; Federico Navarro-Sarabia; Virginia Moreira; Lara Valor; Rosa Garcia-Portales; Ana Marquez; Juan J Gomez-Reino; Javier Martin; Antonio Gonzalez Journal: PLoS One Date: 2019-02-28 Impact factor: 3.240
Authors: Jonathan Massey; Darren Plant; Kimme Hyrich; Ann W Morgan; Anthony G Wilson; Athina Spiliopoulou; Marco Colombo; Paul McKeigue; John Isaacs; Heather Cordell; Costantino Pitzalis; Anne Barton Journal: Pharmacogenomics J Date: 2018-08-31 Impact factor: 3.550